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Abstract
 
Low birth weight in humans is predictive of insulin resis-
tance and diabetes in adult life. The molecular mechanisms
underlying this link are unknown but fetal exposure to ex-
cess glucocorticoids has been implicated. The fetus is nor-
mally protected from the higher maternal levels of glucocor-
ticoids by feto-placental 11
 
b
 
-hydroxysteroid dehydrogenase
type-2 (11
 
b
 
-HSD2) which inactivates glucocorticoids. We
have shown previously that inhibiting 11
 
b
 
-HSD2 through-
out pregnancy in rats reduces birth weight and causes hy-
perglycemia in the adult offspring. We now show that dexa-
methasone (a poor substrate for 11
 
b
 
-HSD2) administered to
pregnant rats selectively in the last week of pregnancy re-
duces birth weight by 10% (
 
P
 
 
 
,
 
 0.05), and produces adult
fasting hyperglycemia (treated 5.3
 
6
 
0.3; control 4.3
 
6
 
0.2 mmol/
liter, 
 
P
 
 
 
5
 
 0.04), reactive hyperglycemia (treated 8.7
 
6
 
0.4;
control 7.5
 
6
 
0.2 mmol/liter, 
 
P
 
 
 
5
 
 0.03), and hyperinsulin-
emia (treated 6.1
 
6
 
0.4; control 3.8
 
6
 
0.5 ng/ml, 
 
P
 
 
 
5
 
 0.01) on
oral glucose loading. In the adult offspring of rats exposed
to dexamethasone in late pregnancy, hepatic expression of
glucocorticoid receptor (GR) mRNA and phosphoenolpyru-
vate carboxykinase (PEPCK) mRNA (and activity) are in-
creased by 25% (
 
P
 
 
 
5
 
 0.01) and 60% (
 
P
 
 
 
,
 
 0.01), respectively,
while other liver enzymes (glucose-6-phosphatase, glucoki-
nase, and 11
 
b
 
-hydroxysteroid dehydrogenase type-1) are
unaltered. In contrast dexamethasone, when given in the
first or second week of gestation, has no effect on offspring
insulin/glucose responses or hepatic PEPCK and GR ex-
pression. The increased hepatic GR expression may be cru-
cial, since rats exposed to dexamethasone in utero showed
potentiated glucose responses to exogenous corticosterone.
These observations suggest that excessive glucocorticoid ex-
posure late in pregnancy predisposes the offspring to glu-
cose intolerance in adulthood. Programmed hepatic PEPCK
overexpression, perhaps mediated by increased GR, may
promote this process by increasing gluconeogenesis. (
 
J.
Clin. Invest.
 
 
 
1998. 101:2174–2181.) Key words: glucocorti-
coids
 
 
 
• 
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b
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• 
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• 
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Introduction
 
Increasing epidemiological evidence in humans suggests a key
role for early life events in the development of cardiovascular
and metabolic disorders (1, 2). In particular, low birth weight is
strongly predictive of hypertension (3), glucose intolerance
(4), non-insulin-dependent diabetes mellitus (NIDDM)
 
1
 
 (5),
and death from ischemic heart disease (1, 2) in adult life. The
association between birth weight and adult disease is indepen-
dent of the classical life-style risk factors such as adult weight,
social class, smoking, alcohol, and lack of exercise (1). Further-
more, these data reflect a continuous relationship representing
birth weights within the normal range, not just severely under-
sized babies (1). These findings have led to the fetal origins
hypothesis which suggests that environmental factors contrib-
uting to the pathogenesis of cardiovascular and metabolic dis-
eases act, in part, in utero (6); thus, an adverse intrauterine en-
vironment would program or imprint the development of fetal
tissues and organs, permanently determining responses, pro-
ducing later dysfunction and disease. The individual organ sys-
tem affected is determined by its unique vulnerability, based
on the timing of the exposure and the systems developing dur-
ing that time window (7).
The mechanisms linking intrauterine growth retardation
and later disease are poorly defined. Recently, we provided
evidence that excessive exposure of the fetus to maternal glu-
cocorticoids might explain the link between low birth weight
and subsequent glucose intolerance (8) and hypertension (9).
Glucocorticoids have well characterized effects on blood pres-
sure and glucose metabolism in the adult (10), and administra-
tion during pregnancy is known to reduce birth weight in hu-
mans and animals (11). Moreover, fetal cortisol levels are
elevated in human intrauterine growth retardation (12). Ste-
roid hormones are also involved in the development and matu-
ration of various fetal and postnatal organ systems (13, 14),
and administration in the perinatal period has been shown to
produce permanent programming effects. Neonatal androgen
administration, for example, permanently influences hepatic
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-hydroxysteroid
dehydrogenase type 2; DEX WK, dexamethasone-treated in week of
gestation; GR, glucocorticoid receptor; IGF, insulin-like growth fac-
tor; IGFBP-1, insulin-like growth factor binding protein-1; NIDDM,
non–insulin-dependent diabetes mellitus; PEPCK, phosphoenolpyru-
vate carboxykinase; pv/pp, perivenous-to-periportal ratio.
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metabolic pathways and sexual behavior (15, 16), while perina-
tal glucocorticoids permanently affect the hypothalamic-pitu-
itary-adrenal axis response to stress (17, 18). Glucocorticoids,
which act via nuclear glucocorticoid receptors (GR) to regu-
late target gene transcription, might act in several ways in a de-
veloping animal to provoke later abnormalities in glucose me-
tabolism. Several important hepatic processes, including many
enzymes controlling the production and fate of metabolic fu-
els, are regulated by glucocorticoids. Phosphoenolpyruvate
carboxykinase (PEPCK), a key enzyme in gluconeogenesis
and an important target gene in NIDDM, is under potent glu-
cocorticoid regulation (19).
The fetus is normally protected from the substantially (5 to
10 times) higher maternal levels of glucocorticoids by placental
11
 
b
 
-hydroxysteroid dehydrogenase type-2 (11
 
b
 
-HSD2). This
enzyme catalyzes the rapid conversion of physiologically active
glucocorticoids (cortisol in humans, corticosterone in rats) to
inert 11-keto products (cortisone and 11-dehydrocorticoste-
rone, respectively) (20, 21). The activity of 11
 
b
 
-HSD2 in the
placenta correlates with birth weight (22). Recently, we have
shown that administration of carbenoxolone (a potent inhibi-
tor of 11
 
b
 
-HSD2) to rats throughout gestation reduces birth
weight and predisposes the offspring to hyperglycemia later in
life (7). To test that this effect of carbenoxolone was produced
by exposing the fetus to raised levels of glucocorticoids rather
than less specific effects on other enzymes (such as 11
 
b
 
-HSD1,
a reductase enzyme which amplifies glucocorticoid action by
regenerating active 11-hydroxy forms from inert 11-keto ste-
roids), we used dexamethasone, a synthetic glucocorticoid
which is a poor substrate for 11
 
b
 
-HSD2 (20). Thus, the goals
of these studies were: (
 
a
 
) to examine whether exposure to ex-
cess glucocorticoids during intrauterine development perma-
nently programs abnormal glucose metabolism in the off-
spring, (
 
b
 
) to determine the critical prenatal period(s) when
glucocorticoids alter glucose metabolism, and (
 
c
 
) to examine
the effects of prenatal glucocorticoids upon gene expression
and activity of key enzymes involved in hepatic glucose metab-
olism and glucocorticoid action.
 
Methods
 
Animals.
 
Female Wistar rats (200–250 g; Harlan UK Ltd., Bicester,
UK) were maintained under conditions of controlled lighting (lights
on 7:00 a.m. to 7:00 p.m.) and temperature (22
 
8
 
C) and allowed free
access to food (standard rat chow; 56.3% carbohydrate, 18.3% pro-
tein, 0.7% NaCl; Bruce Smith and Smart Scotland Ltd. Edinburgh)
and tap water. The rats were time-mated and divided into four treat-
ment groups (five females per group). Dexamethasone (100 
 
m
 
g/kg
per d, dissolved in 4% ethanol–0.9% saline, 200 
 
m
 
g/ml) was given
subcutaneously during the first (dexamethasone-treated in week of
gestation [DEX WK] 1), DEX WK2, or DEX WK3, with vehicle in-
jections in other weeks; a control group received an injection of vehi-
cle alone throughout pregnancy (
 
Control
 
). On day 19 of pregnancy,
maternal tail tip blood samples were collected to determine plasma
glucose. At birth, the offspring were weighed. Male offspring, se-
lected at random from each litter, were used in all subsequent experi-
ments.
 
Oral glucose tolerance test.
 
The offspring underwent an oral glu-
cose tolerance test at 6 mo. Animals were fasted overnight and tests
were started between 8:30 and 9:00 a.m. the following morning. An
oral glucose load of 2 g/kg was given by gavage and tail tip samples
were collected in heparinized Eppendorf tubes at 0, 30, and 120 min.
Plasma was stored at 
 
2
 
20
 
8
 
C.
Glucose was determined by the enzymatic (hexokinase) method
using a glucose assay kit supplied by Sigma Chemical Co. (Poole, UK).
The intraassay and interassay coefficients of variation were 
 
,
 
 2%. In-
sulin was measured by radioimmunoassay (rat insulin [
 
125
 
I] assay sys-
tem; Amersham International, Buckinghamshire, UK). The intraas-
say and interassay coefficients of variation were 
 
,
 
 10 and 
 
,
 
 15%,
respectively.
 
Corticosterone implants.
 
At 5 mo, blood samples were collected
by tail tipping to determine basal (8:30 a.m.) plasma corticosterone
levels. Corticosterone was measured by specific radioimmunoassay,
as described by MacPhee et al. (23). To determine the effect of exog-
enous corticosterone on blood glucose concentration, four pellets of
corticosterone acetate (250 
 
m
 
g/d corticosterone) were given subcuta-
neously under halothane anesthesia (controls were sham operated).
Fasting blood glucose was measured 3 d after pellets were inserted.
After a week, animals were fasted overnight and, after decapitation,
their livers removed for GR binding studies and mRNA expression.
 
GR binding studies.
 
Cytosol was prepared from fragments of ex-
cised livers for dexamethasone and corticosterone binding studies, as
described previously (24). Briefly each liver sample was homogenized
in 10 mM Tris-HCl buffer (pH 7.4) containing 2 mM DTT, 1.5 mM
EDTA, 0.1 M sodium molybdate, and 10% glycerol. After centrifuga-
tion (4
 
8
 
C) at 20,000 and 105,000 
 
g
 
 for 20 and 60 min, respectively, the
protein content was adjusted to 4 mg/ml. Aliquots (50 
 
m
 
l) of liver cys-
tol were incubated for 16 h at 4
 
8
 
C in buffer with 1.5 nM [
 
3
 
H]dexa-
methasone (Amersham International) and various concentrations of
either nonradioactive dexamethasone or corticosterone (0.316 nM–
100 
 
m
 
M). Free and bound radioactivity were separated with dextran-
coated charcoal (5 g/liter charcoal and 1 g/liter dextran T70 in buffer)
and bound radioactivity was counted in a liquid scintillation spec-
trometer (Wallac, Crownhill, UK). Binding constants for dexametha-
sone and corticosterone were calculated from homologous and heter-
ologous competition curves.
 
Enzyme activity.
 
Fed animals were killed by decapitation between
9:00 and 10:00 a.m. and livers were removed immediately. 10% (wt/vol)
fresh liver homogenates were prepared at 0
 
8
 
C in medium containing
250 mM sucrose and 5 mM Hepes (pH 7.4). Homogenates were cen-
trifuged at 3,600 
 
g
 
 for 10 min to sediment intact cells. The supernatant
fractions were further centrifuged at 130,000 
 
g
 
 for 30 min. The result-
ing supernatant (cytosol) was collected and stored at 
 
2
 
70
 
8
 
C for
PEPCK and glucokinase assay. The pellet (microsomal fraction) was
resuspended in buffer and stored at 
 
2
 
70
 
8
 
C for glucose-6-phosphate
assay. Protein content of the preparations was determined by the
Peterson method (25). PEPCK activity was assayed at 30
 
8
 
C by cou-
pling the formation of oxalacetate with NADH oxidation in the pres-
ence of excess malate dehydrogenase (Boehringer Mannheim UK,
Lewes, UK), as described by Petrescu et al. (26). The reaction mix-
ture (1 ml final volume) contained 50 mM Hepes (pH 6.5), 50 mM so-
dium bicarbonate, 1 mM MnCl
 
2
 
, 0.25 mM NADH, 1 mM phospho-
enolpyruvate, 1.5 U malate dehydrogenase, and 100 
 
m
 
l of liver cytosolic
preparation. The reaction was initiated with 0.15 mM deoxy-GDP
and the decrease in absorbance at 340 nm was followed for 5 min. A
reaction mixture lacking bicarbonate was used as control. Glucoki-
nase was assayed using a continuous spectrometric method adopted
from Davidson and Arion (27). The assay medium contained 50 mM
sodium Hepes, 100 mM KCl, 7.5 mM MgCl
 
2
 
, 5 mM ATP, 2.5 mM
DTT, 100 mM glucose, 0.5 mM NAD
 
1
 
, and 1 U of glucose-6-phos-
phate dehydrogenase (Sigma Chemical Co.). The activity of 0.01 ml of
cytosolic preparation was assayed in a final volume of 1 ml. The reac-
tion was initiated by addition of ATP and the rate of NAD
 
1
 
 reduc-
tion was recorded at 340 nm. Control medium lacked ATP. Glucose-
6-phosphatase activity (in intact and disrupted microsomes) was
assayed kinetically as described previously (28).
 
RNA probes.
 
All restriction enzymes and RNA polymerases
were obtained from Promega UK Ltd. (Southampton, UK). A 360-bp
fragment derived from the coding region of rat PEPCK cDNA was
generated by PCR using two primers (5
 
9
 
 AGCTGCATAATG-
GTCTGG 3
 
9
 
 and 5
 
9
 
 GAACCTGGCGTTGAATGC 3
 
9
 
), and cloned
into the pGEM-T easy vector (Promega UK Ltd.). Fidelity of amplifi-
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cation was confirmed by sequencing. The complementary antisense
RNA strand was generated by SP6 RNA polymerase after NcoI lin-
earization of the vector. Noncomplementary sense strand was tran-
scribed by T7 RNA polymerase from SacI-linearized vector. GR tem-
plates were made from a 674-bp fragment of rat GR cDNA subcloned
into pGEM3 (29). The sense strand was transcribed using SP6 RNA
polymerase whereas the antisense strand was obtained from T7 RNA
polymerase transcription. The 11
 
b
 
-HSD1 antisense template was
transcribed by T3 polymerization from pBluescript vector containing
a 1.2-kb 11
 
b
 
-HSD1 cDNA insert (30); T7 RNA polymerase was used
to make the sense transcript. Radioactive probes were synthesized by
incubating the appropriate RNA polymerase (15 U) with 0.5 
 
m
 
g of
linearizd plasmid, 1
 
3
 
 transcription buffer, 10 mM DTT, 3 mM ATP/
GTP/CTP, 200 
 
m
 
Ci[
 
a
 
-
 
35
 
S]UTP (Amersham International), and 4 U
RNase inhibitor in a total volume of 10 
 
m
 
l for 1 h at 37
 
8
 
C (or 40
 
8
 
C
for SP6 RNA polymerase). 10 
 
m
 
l of 0.1 U of DNase1 in 1
 
3
 
 transcrip-
tion buffer was added to the mixture and incubated for further 10
min. Unincorporated nucleotides were removed by running the probe
through a Sephadex G-50 column (Pharmacia Biotech, St. Albans, UK).
 
In situ hybridization.
 
Livers were removed after decapitation and
fragments quickly frozen in liquid nitrogen and stored at 
 
2
 
70
 
8
 
C. In
situ hybridization was performed as described previously (31). In
brief, cryostat sections (10 
 
m
 
m) were mounted on poly-
 
L
 
-lysine–
coated slides and fixed for 10 min in 4% paraformaldehyde solution
in 0.1 M phosphate buffer (pH 7.4) and washed three times in 2
 
3
 
SSC. Antisense transcripts were diluted in hybridization buffer to
5 
 
3 
 
10
 
6
 
 cpm/
 
m
 
l. The hybridization mixture contained 0.5 M NaCl,
0.01 M Tris, 1 mM EDTA, 10 mM DTT, 10% dextran sulphate, 1
 
3
 
Denhardt’s solution, 2 
 
m
 
g/ml herring testis DNA, 0.125 mg/ml yeast
tRNA, and 50% (vol/vol) deionized formamide. Hybridization was
carried out overnight at 55
 
8
 
C in a chamber humidified with 50%
deionized formamide/4
 
3
 
 SSC. After washes (three times, room tem-
perature) in 2
 
3
 
 SSC, the sections were treated with 30 
 
m
 
g/ml bovine
pancreatic RNase A (Boehringer Mannheim UK) in buffer contain-
ing 0.5 M NaCl, 0.01 M Tris, and 1 mM EDTA and incubated for 1 h
at 37
 
8
 
C. The sections were then washed in 2
 
3
 
 SSC at room tempera-
ture for 30 min and twice in 0.1
 
3
 
 SSC at 60
 
8
 
C for 30 min. After de-
hydration in graded ethanol the slides were dipped in Kodak (Ro-
chester, NY) NTB 2 emulsion diluted 1:1 with distilled water.
Autoradiography was performed at 4
 
8
 
C for 3 wk. After development,
sections were counterstained with hematoxylin and eosin. The hy-
bridization signal was quantified by counting silver grains in the peri-
portal or perivenous regions under bright-field illumination using a
computer driven image analysis system (Seescan, Cambridge, UK).
Specificity of hybridization was demonstrated using labeled sense
RNA probes hybridized under identical conditions. No specific hy-
bridization was seen with any sense probe (data not shown).
 
Statistics.
 
All data are expressed as mean
 
6
 
SEM. Data were com-
pared using an unpaired Student’s 
 
t
 
 tests or one-way ANOVA fol-
lowed by a Newman-Keuls post-hoc multiple comparisons test where
appropriate. Values were considered significant when 
 
P
 
 
 
,
 
 0.05.
 
Results
 
The effect of prenatal dexamethasone on offspring birth
weight.
 
Dexamethasone treatment did not affect maternal glu-
cose levels, and there were no differences in length of gesta-
tion, litter size, or viability among the groups (data not shown).
However, dexamethasone administration in the third week of
pregnancy reduced offspring birth weight (treated 5.6
 
6
 
0.1;
control 6.2
 
6
 
0.1 g, 
 
P
 
 
 
5
 
 0.004). Treatment during the first or
second week of gestation had no significant effects on birth
weight (Table I). Body weights of all 3 dexamethasone-treated
and control groups were similar at time of weaning (day 21 af-
ter birth) and at 6 mo (Table I).
 
The effect of prenatal dexamethasone treatment on glucose
homeostasis.
 
At 6 mo, offspring of dams that had dexametha-
sone during the last week of pregnancy had significantly higher
fasting plasma glucose concentrations than controls (5.3
 
60.3 vs.
4.360.2 mmol/liter, P 5 0.04). A randomly selected subset of
each group was used for oral glucose tolerance tests. After an
Table I. Effect of Dexamethasone on Offspring Body Weights
Group Birth weight Weight at day 21 Weight at 6 mo
g g g
Control 6.260.1 (n 5 27) 47.363.3 (n 5 11) 455.6622.4 (n 5 9)
DEX WK1 6.560.1 (n 5 28) 49.760.9 (n 5 8) 454.7627.3 (n 5 9)
DEX WK2 6.160.1 (n 5 31) 50.461.0 (n 5 12) 458.5618.2 (n 5 13)
DEX WK3 5.660.1* (n 5 33) 48.861.3 (n 5 8) 445.8617.8 (n 5 11)
Body weights (grams) of the offspring of pregnant rats treated with ve-
hicle alone (Control), DEX WK1, DEX WK2, or DEX WK3 were mea-
sured at birth, day 21, and 6 mo. *P , 0.01 compared with control.
Figure 1. Plasma glucose and insulin responses to an oral glucose 
load in offspring. Offspring of pregnant rats that received vehicle 
alone (CONTROL, n 5 9), DEX WK1 (n 5 8), DEX WK2 (n 5 13), 
or DEX WK3 (n 5 8) underwent an oral glucose tolerance test at 6 mo. 
Plasma glucose (A) was measured at 0, 30, and 120 min and insulin 
(B) was measured at 0 and 30 min after oral glucose load. *P , 0.05 
compared to control.
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oral glucose load, DEX WK3 offspring had significantly higher
30-min plasma glucose concentrations compared to control
(8.760.4 vs. 7.560.2 mmol/liter, P 5 0.03). There were no sig-
nificant differences at 120 min (Fig. 1 A). Fasting plasma insu-
lin levels were similar in all the groups, but DEX WK3 off-
spring had higher 30-min insulin levels after glucose loading
than controls (6.160.4 vs. 3.860.5 ng/ml, P 5 0.01) (Fig. 1 B).
DEX WK3 Offspring also showed an elevated 30-min insulin-
to-glucose ratio compared to controls (0.7160.06 vs. 0.5060.07
mg/mmol, P 5 0.03), suggesting more insulin secretion per unit
of glucose. Dexamethasone administration during either the
first or second week of gestation did not significantly affect
glucose or insulin levels in the adult offspring.
The effect of prenatal dexamethasone treatment on mRNA
expression and activity of hepatic enzymes. Enzyme expression
and activity was determined in livers of fed rats. Within the he-
patic acinus, PEPCK mRNA expression was higher in the peri-
portal zone than in the perivenous zone in all the groups. This
zonation was age-dependent, with the perivenous-to-peripor-
tal (pv/pp) ratio increasing from 1:1.5 at birth and peaking to 1:3
by weaning. Dexamethasone administration during the first or
second week of gestation significantly reduced periportal
PEPCK mRNA expression in the offspring from birth up to 21 d;
at 8 mo expression was similar to control (Fig. 2). In contrast,
treatment during the third week of pregnancy had no effect on
PEPCK expression at birth but permanently increased peri-
portal PEPCK expression from day 5 after birth onwards (Fig.
2). Perivenous PEPCK mRNA expression was not signifi-
cantly affected by prenatal dexamethasone (data not shown).
PEPCK enzyme activities were correspondingly increased in
DEX WK3 offspring compared to controls (Fig. 3). Neither
glucose-6-phosphatase nor glucokinase activity was affected by
dexamethasone treatment (data not shown).
The effect of prenatal dexamethasone on hepatic GR expres-
sion. GR mRNA was widely expressed in the liver, with high-
est levels in the periportal region (pv/pp of 1:1.4). DEX WK3
offspring significantly elevated hepatic GR mRNA expression.
(Fig. 4.). The increase in GR was maintained to adult life, but
was more marked at day 5 after birth (70%) than at 8 mo
(25%). The binding affinity of GR was unaltered by prenatal
dexamethasone treatment (Table II).
The effect of prenatal dexamethasone on expression of he-
patic 11 b-HSD1. 11b-HSD1 was highly expressed in the liver.
The distribution of 11b-HSD1 mRNA within the acini was
similar to that of GR mRNA, with a pv/pp ratio of 1:1.3. Pre-
natal dexamethasone administration did not affect levels of ex-
pression or distribution of 11b-HSD1 (Fig. 4.).
The effect of exogenous corticosterone on hepatic GR ex-
pression. As hepatic GR mRNA was increased in animals that
had dexamethasone late in pregnancy, we examined whether
this was functionally important by measuring basal (8:30 a.m.)
plasma corticosterone levels and by examining whether exoge-
nous corticosterone modulated GR mRNA expression. There
were no significant differences in basal plasma corticosterone
levels between offspring of dams that had dexamethasone dur-
ing the third week of pregnancy and controls (DEX WK3,
3.260.4; Control, 2.560.6 P 5 0.4). Exogenous corticosterone
pellets did not affect the dissociation constant of hepatic GR
(Table II), but significantly reduced expression of hepatic
GR mRNA in DEX WK3 offspring (Fig. 5). The decrease in
GR mRNA expression in controls did not reach statistical sig-
Figure 2. Effect of prenatal dexamethasone on periportal PEPCK 
mRNA expression in the offspring. Hepatic PEPCK mRNA expres-
sion in fed offspring of dams that received vehicle alone (CON-
TROL), DEX WK1, DEX WK2, or DEX WK3 was measured by in 
situ hybridization at days 1, 5, and 21, and at 8 mo of age. Results rep-
resent periportal expression as a percentage of control. * P , 0.05 
compared to control.
Figure 3. Effect of prenatal dexamethasone on hepatic enzyme activ-
ities. Activity of hepatic PEPCK was assayed in fed offspring (days 5 
and 21 and at 8 mo of age) of dams that had vehicle alone (CON-
TROL) or DEX WK3. For controls, n was 11, 11, and 9 at days 5, and 
21 and at 8 mo, respectively. For DEX WK3 n was 12, 7, and 12 at 
days 5, and 21 and at 8 mo, respectively). **P , 0.01, *P , 0.05 com-
pared with control.
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nificance. Even after exogenous corticosterone, GR mRNA
expression in animals exposed to dexamethasone in utero re-
mained higher than similarly treated controls (Fig. 5). Exoge-
nous corticosterone significantly increased fasting plasma glu-
cose levels in DEX WK3 offspring while levels in controls
were unchanged (Fig. 6).
Discussion
We have shown that dexamethasone administration in the
pregnant rat, selectively in the last week of gestation, reduces
birth weight and produces fasting and postglucose hyperglyce-
mia and hyperinsulinemia in the adult offspring. These find-
ings are in accord with our earlier observations in which the
physiological barrier to glucocorticoids, 11b-HSD2, was inhib-
ited by carbenoxolone throughout pregnancy (8), and directly
demonstrate that prenatal exposure to elevated glucocorticoid
levels programs glucose metabolism, leading to permanent hy-
perglycemia and apparent insulin resistance. The effect on
both birth weight and glucose–insulin homeostasis of the off-
Figure 4. Effect of prenatal dexamethasone on periportal GR and 
11b-HSD1 mRNA expression in the offspring. Hepatic GR and 11b-
HSD1 mRNA expression in fed offspring of dams that received vehi-
cle alone (CONTROL) or DEX WK3 was measured by in situ hy-
bridization at the ages of 5 d and 8 mo. Results are expressed as a per-
centage of periportal mRNA in control.
Table II. Hepatic GR Binding Affinity
Group Kd Dex Kd B B max
nM nM nmol/g protein
Control1Sham 4.560.4 10.661.6 0.2960.05
Control1Cort 5.360.4 10.162.6 0.2460.03
DEX WK31Sham 4.460.8 8.661.3 0.3760.07
DEX WK31Cort 5.160.7 11.562.2 0.2660.04
Adult DEX WK3 offspring were given subcutaneous corticosterone
pellets (DEX WK31Cort, n 5 6) or sham operated (DEX WK31Sham,
n 5 6). Similarly, offspring of vehicle-treated dams received corticoste-
rone pellets (Control1Cort, n 5 6) or sham operation (Control1Sham,
n 5 6). 1 wk after operation, GR binding affinity for ligand was deter-
mined on liver cytosols of fasted rats. Binding constants for dexametha-
sone (Dex) and corticosterone (B) were calculated from homologous
and heterogous competition curves.
Figure 5. Effect of exogenous corticosterone on hepatic GR expres-
sion. Adult offspring of dams that had vehicle (CONTROL) or DEX 
WK3 were given subcutaneous corticosterone pellets (CORT) or 
sham operated (SHAM). 1 wk after the operation, hepatic GR 
mRNA expression in fasted rats was measured by in situ hybridiza-
tion. Results represent periportal mRNA expression as a percentage 
of control. n 5 6 per group. *P , 0.05 for corticosterone vs. sham-
operated in DEX WK3 animals; §P , 0.05 for DEX vs. control in ani-
mals that had corticosterone.
Figure 6. The effect of corticosterone pellets on fasting plasma glu-
cose. Adult offspring of dams that had vehicle (CONTROL) or DEX 
WK3 were given subcutaneous corticosterone pellets (CORT) or 
sham operated (SHAM). Plasma glucose was measured on the third 
day after the operation, after an overnight fast. n 5 6 per group. *P , 
0.05 for corticosterone vs. sham-operated in DEX WK3 animals.
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spring only occurred when dexamethasone was administered
during the third week of gestation and not earlier in preg-
nancy, suggesting a late gestational window of sensitivity to
glucocorticoids. The nature of the late period of sensitivity to
glucocorticoids is uncertain; GR are expressed in many tissues,
including liver, from midgestation onwards (32). Perhaps the
congruence of rapid growth in late gestation with the expres-
sion of key glucocorticoid-regulated growth factors, such as
the insulin-like growth factor (IGF) system, may be of impor-
tance. Indeed hepatic production of IGF binding protein-1
(IGFBP-1), which neutralizes the actions of IGF-1, is mark-
edly induced in late gestation fetuses by high-dose maternal
dexamethasone treatment (33), and has been advocated as
causal in the growth retardation observed. Furthermore, trans-
genic mice overexpressing IGFBP-1 have low birth weight and
adult hyperglycemia (34), perhaps suggesting one mechanism
through which glucocorticoids link low birth weight and ab-
normal glucose metabolism. However, these programming
mechanisms are likely to be complex because GR mediates its
effects by interacting with several factors. For example, regula-
tion of IGFBP-1 by glucocorticoids involves interaction of GR
with hepatic nuclear factor-1 (35), which has been causally
linked to diabetes (36). Whatever the mechanisms, the effects
of late prenatal glucocorticoids mimic, and might therefore un-
derlie, the human epidemiological associations between low
birth weight and later glucose intolerance/NIDDM.
The basis of NIDDM is incompletely understood, but in-
creased hepatic glucose production may be a major contribut-
ing factor (37). In adult life, glucocorticoids affect glucose-
insulin homeostasis at several levels, by inducing peripheral
insulin resistance (38), inhibiting insulin secretion (39), and
stimulating gluconeogenesis (37). In early life, glucocorticoids
exert important maturational effects on enzymes involved in
glucose metabolism, most notably PEPCK (13, 14, 40). Our re-
sults show that treatment with dexamethasone during the third
week of pregnancy induces permanent overexpression of
PEPCK in the offspring, with no effect on glucose-6-phos-
phatase (another gluconeogenic enzyme) or glucokinase (a
glycolytic enzyme), though the decline in the latter ap-
proached significance. The effects on PEPCK were transcrip-
tional, in accord with the predominant level of control of this
gene product, and were specifically confined to periportal re-
gions, the major sites of gluconeogenesis in the hepatic acinus.
Selective increases in gluconeogenic enzyme activity have
been documented in various animal models of NIDDM (41,
42). Since PEPCK is the rate limiting enzyme of gluconeogen-
esis (43), and overexpression of PEPCK in a rat hepatoma cell
line impairs suppression of gluconeogenesis (44), it is plausible
that increased PEPCK in vivo potentiates hepatic glucose pro-
duction, producing the observed glucose intolerance. Indeed,
transgenic mice overexpressing PEPCK have impaired glucose
tolerance (45).
The mechanism by which PEPCK expression is increased
by exposure to dexamethasone in utero is unclear. In the adult
rat liver, PEPCK gene transcription is increased by glucocorti-
coids, glucagon (through cAMP), thyroid hormone and retin-
oic acid, and is negatively and dominantly regulated by insulin
(46, 47). The PEPCK gene promoter has two distinct cis ele-
ments which are bound by activated GR (48). PEPCK appears
in liver with the first lactational feed on the day of birth (49),
and is associated with the increase in glucagon-to-insulin ratio
(50) and/or the rise in glucocorticoids (40) that occurs at this
time. Indeed PEPCK can be induced prematurely by injection
of glucagon (51, 52), cAMP (49), and glucocorticoids, at least in
the chick (53) and sheep (40). However, in this study dexameth-
asone in the last week of pregnancy did not alter PEPCK ex-
pression at birth, but only from day 5, suggesting an indirect
effect. The actions of glucocorticoids in the liver are modu-
lated by 11b-HSD1 which amplifies intrahepatic glucocorti-
coid action by catalyzing the conversion of the ample supply of
inert circulating metabolites (cortisone and 11-dehydrocorti-
costerone) into bioactive glucocorticoids (cortisol and corti-
costerone) (54). Indeed, mice with targeted disruption of the
11b-HSD1 gene show deficient induction of gluconeogenic en-
zymes (55). However, 11b-HSD1 expression was unaltered by
prenatal dexamethasone, and was not enriched periportally,
providing no support for this idea.
In contrast, prenatal dexamethasone permanently increased
GR expression in the liver. The increase in hepatic GR mRNA
expression occurred in the presence of maintained (i.e., unsup-
pressed) circulating glucocorticoids and unaltered GR binding
affinity for ligand. This is an intriguing finding, since GR
mRNA levels are often negatively autoregulated by circulating
glucocorticoids (56). Indeed exogenous corticosterone admin-
istration achieved some downregulation of GR mRNA in
these animals. However, hepatic GR levels in animals exposed
to dexamethasone in utero remained higher than similarly
treated controls. This finding suggests that glucocorticoids are
able to downregulate GR in offspring of dexamethasone-
treated dams, but that the basal set point of hepatic GR
expression is higher compared to controls. Several, possibly
species-specific, molecular mechanisms of regulation of GR
expression have been suggested. In the mouse GR expression
is controlled by at least three promoters, one of which is pref-
erentially used in T lymphocytes (57). Rat mRNA also shows
high variability at the 59 end, suggesting expression from dif-
ferent transcriptional start sites and/or promoters (58). The
rise in hepatic GR mRNA expression in offspring that were
exposed to dexamethasone in utero, may well reflect induction
of a liver-specific promoter, since GR mRNA is decreased by
the same treatment in hippocampal neurons (18). Increased
hepatic GR expression, in the presence of maintained cortico-
sterone levels and unaltered GR binding affinity, suggests that
prenatal dexamethasone may program enhanced glucocorti-
coid mediated responses, such as induction of hepatic PEPCK
expression. This contention is supported by the increased
blood glucose sensitivity which these rats show to exogenous
glucocorticoids. The lack of effect on other glucocorticoid-sen-
sitive mRNAs and enzymes may well reflect the complex con-
trol of these gene products.
Fetal nutrition is also important in determining prenatal
growth and maternal lack of nutrition is associated with later
disease, including hypertension and diabetes (2). Specifically,
maternal protein restriction during rat pregnancy produces
offspring showing hypertension and hyperglycemia, with al-
tered hepatic enzyme profiles including increased PEPCK ac-
tivity (59). It is possible that the effects of glucocorticoids and
lack of nutrition have a common underlying mechanism. In-
deed maternal protein restriction during rat pregnancy attenu-
ates placental 11b-HSD2 activity (60), suggesting that exces-
sive glucocorticoid exposure may mediate, in part, the effects
of a lack of nutrition. Moreover, hypertension induced by a
maternal low-protein diet in the rat is prevented by inhibitors
of glucocorticoid synthesis (61). Thus, fetal overexposure to
2180 Nyirenda et al.
glucocorticoids may represent a common link between the ma-
ternal environment, fetal growth, and later cardiovascular and
metabolic diseases, notably NIDDM.
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